Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping ...
Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.
Novo Nordisk is finally getting one up on its biggest rival.
24/7 Wall St. on MSN
Wall Street is betting on Eli Lilly’s GLP-1 portfolio — it’s missing the $1 trillion opportunity
Quick ReadJPMorgan raised Lilly to $1,400 and RBC to $1,500, with both banks anchoring their bull cases almost entirely on ...
Shares of Eli Lilly have risen by over 40% since the company last reported earnings.
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...
During the last three months, 7 analysts shared their evaluations of Eli Lilly (NYSE:LLY), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, ...
A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." Fourth-Quarter Reported ResultsIn Q4 ...
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many ...
13 analysts have shared their evaluations of Eli Lilly (NYSE:LLY) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results